Security key
690469101
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 47,565,663
- Total 13F value
- $44,391,185
- Share change
- +1,217,062
- Put/Call ratio
- 8.3%
- SEC-reported price per share
- $0.93
- Number of holders
- 80
- Value change
- +$933,718
- Number of buys
- 35
- Number of sells
- 27
- Shares outstanding
- 186,597,793
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2024
Institutions
80
Top holders
10
OVID full security history
Ownership snapshot
Full 13F holder table
Ovid Therapeutics Inc. SEC filings
Ovid Therapeutics Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of OVID - Ovid Therapeutics Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Madison Avenue Partners, LP
Disclosed value leader
TAKEDA PHARMACEUTICAL CO LTD
Comparable rows
15/15
Latest evidence
30 Sep 2024
13F
13D/G
Lead comparable stake: 4%
13D/G row: Madison Avenue Partners, LP
Showing 1-6 of 15 holder rows.
Quick read
Madison Avenue Partners, LP leads the comparable SEC ownership view at 4%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Madison Avenue Partners, LP's linked filing trail.
Comparable ownership
Top 5
Madison Avenue Partners, LP
4%
TAKEDA PHARMACEUTICAL CO LTD
4%
Rubric Capital Management LP
2.8%
BlackRock, Inc.
2.3%
BVF INC/IL
2.1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Madison Avenue Partners, LP |
13F
13D/G
Company
|
4%
from 13D/G
|
$4,857,793
4,116,773 shares
|
— | 30 Sep 2024 |
| TAKEDA PHARMACEUTICAL CO LTD |
13F
Company
|
4%
|
$8,887,755
7,531,996 shares
|
— | 30 Sep 2024 |
| Rubric Capital Management LP |
13F
Company
|
2.8%
|
$6,272,843
5,315,969 shares
|
— | 30 Sep 2024 |
| BlackRock, Inc. |
13F
Company
|
2.3%
|
$5,091,036
4,314,437 shares
|
— | 30 Sep 2024 |
| BVF INC/IL |
13F
Company
|
2.1%
|
$4,547,505
3,853,818 shares
|
— | 30 Sep 2024 |
| VANGUARD GROUP INC |
13F
Company
|
1.7%
|
$3,708,078
3,142,439 shares
|
— | 30 Sep 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
80
Shares
47,565,663
Rows available
80
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2024 vs Q3 2024 Across Filers
Q3 2024 holders
75
Q4 2024 holders
80
Holder diff
5
| Investor | Q3 2024 Shares | Q4 2024 Shares | Share Diff | Share Chg % | Q3 2024 value | Q4 2024 value | Value change | Value Chg % |
|---|